Lasinone 5mg Capsule contains Nitisinone, a potent inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD). It is primarily indicated for the treatment of hereditary tyrosinemia type 1 (HT-1), a rare metabolic disorder characterized by the accumulation of toxic metabolites due to a deficiency in fumarylacetoacetate hydrolase. By inhibiting HPPD, Nitisinone reduces the production of harmful metabolites such as succinylacetone, thereby preventing liver and kidney damage associated with HT-1. Lasinone is administered orally, with a recommended dosage tailored to patient weight and clinical response, under strict medical supervision. The drug demonstrates a favorable pharmacokinetic profile, with good oral bioavailability and a prolonged half-life, allowing for convenient dosing schedules. Common adverse effects may include mild gastrointestinal disturbances, elevated plasma tyrosine levels, and potential ocular symptoms; hence, regular monitoring of plasma tyrosine concentrations and liver function tests is advised during therapy. Lasinone should be used cautiously in patients with hypersensitivity to Nitisinone or its excipients. It is contraindicated in individuals with known hypersensitivity and should be avoided during pregnancy unless the potential benefit outweighs the risk. Overall, Lasinone 5mg Capsule represents a critical therapeutic option in managing HT-1, improving patient prognosis and quality of life through effective metabolic control.